Biparatopic LRP6-targeted bispecific ADC (antibody-drug conjugate) is an innovative approach in cancer therapy that combines the specificity of a bispecific antibody with the potent cytotoxic effects of a chemotherapeutic drug. LRP6, a key co-receptor involved in the Wnt/β-catenin signaling pathway, plays a critical role in tumor progression and metastasis. By targeting LRP6 with a biparatopic bispecific antibody, the ADC is able to selectively bind to two distinct epitopes on LRP6, enhancing its precision in targeting cancer cells. The conjugated cytotoxic drug is then delivered directly to the tumor site, minimizing damage to healthy tissues and improving the therapeutic efficacy. This targeted delivery strategy offers significant promise in treating cancers where LRP6 overexpression contributes to tumor growth and resistance to conventional therapies. Ongoing research into biparatopic LRP6-targeted bispecific ADCs aims to optimize their design, increase their selectivity, and reduce potential side effects, making them a promising candidate for advanced cancer therapies.
